Santhera Pharmaceuticals Holding AG

BATS-CHIXE:SANNZ Stock Report

Market Cap: CHF 126.6m

Santhera Pharmaceuticals Holding Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Dario Eklund

Chief executive officer

CHF 1.7m

Total compensation

CEO salary percentage30.1%
CEO tenure5yrs
CEO ownership0.04%
Management average tenureless than a year
Board average tenure4.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Dario Eklund's remuneration changed compared to Santhera Pharmaceuticals Holding's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

CHF 63m

Mar 31 2024n/an/a

CHF 59m

Dec 31 2023CHF 2mCHF 516k

CHF 55m

Sep 30 2023n/an/a

-CHF 5m

Jun 30 2023n/an/a

-CHF 65m

Mar 31 2023n/an/a

-CHF 68m

Dec 31 2022CHF 2mCHF 505k

-CHF 71m

Sep 30 2022n/an/a

-CHF 68m

Jun 30 2022n/an/a

-CHF 65m

Mar 31 2022n/an/a

-CHF 60m

Dec 31 2021CHF 1mCHF 500k

-CHF 56m

Sep 30 2021n/an/a

-CHF 56m

Jun 30 2021n/an/a

-CHF 56m

Mar 31 2021n/an/a

-CHF 62m

Dec 31 2020CHF 681kCHF 500k

-CHF 68m

Sep 30 2020n/an/a

-CHF 46m

Jun 30 2020n/an/a

-CHF 24m

Mar 31 2020n/an/a

-CHF 21m

Dec 31 2019CHF 2mCHF 42k

-CHF 19m

Compensation vs Market: Dario's total compensation ($USD1.92M) is above average for companies of similar size in the UK market ($USD347.06K).

Compensation vs Earnings: Dario's compensation has been consistent with company performance over the past year.

CEO

Dario Eklund (56 yo)

5yrs

Tenure

CHF 1,715,974

Compensation

Mr. Dario Eklund has been Chief Executive Officer at Santhera Pharmaceuticals Holding AG since December 1, 2019. He served as Head of Global Business Operations at Vifor Pharma Ltd. since 2014.He served a...

Leadership Team

NamePositionTenureCompensationOwnership
Thomas Meier
Founder & Chairman7.7yrsCHF 200.00k0.26%
CHF 325.1k
Dario Eklund
Chief Executive Officer5yrsCHF 1.72m0.037%
CHF 47.1k
Andrew Smith
Chief Financial Officer4.7yrsno datano data
Oliver Strub
Head of Complianceless than a yearno datano data
Shabir Hasham
Chief Medical Officerno datano data0.022%
CHF 27.7k
Marc Schrader
Chief Technology Officerless than a yearno datano data
Oliver Kronenberg
Chief Legal Officer & Corporate Secretaryless than a yearno datano data
Neville Kodkani
Head of Global Marketing & Partner Managementno datano datano data
Sarah Holmes-Klotz
Head of People & Culture2.8yrsno datano data
Andreas Missy
Executive Vice President of Corporate Planning & Business Developmentno datano datano data
Geert van Daal
Chief Commercial Officerno datano datano data
Ana Vera
Head of Development & Deputy CMOless than a yearno datano data

0.9yrs

Average Tenure

61.5yo

Average Age

Experienced Management: SANNZ's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Thomas Meier
Founder & Chairman7.7yrsCHF 200.00k0.26%
CHF 325.1k
Otto Schwarz
Director1.5yrsCHF 143.75kno data
Bradley Meyer
Director1.5yrsCHF 168.75k0.026%
CHF 32.3k
Philipp Gutzwiller
Non Executive Independent Director7.7yrsCHF 145.00k0.11%
CHF 141.2k

4.6yrs

Average Tenure

59yo

Average Age

Experienced Board: SANNZ's board of directors are considered experienced (4.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 15:10
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Santhera Pharmaceuticals Holding AG is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Maurizio BernasconiBank am Bellevue
Silvia SchanzBank Vontobel AG
Barbora BlahaCredit Suisse